Molnupiravir

Treatment of COVID-19

Molnupiravir is used to treat mild-to-moderate COVID-19 in adults who have received a positive result from a direct SARS-CoV-2 viral test. It is specifically intended for individuals who are at a high risk of progressing to severe COVID-19, which may include hospitalization or death.

Clinical Use and Eligibility

This medication is typically prescribed when other COVID-19 treatment options authorized by the FDA are not accessible or are not clinically appropriate for the patient. It is not intended for general use in all people who test positive for the virus.

Limitations of Use

There are specific situations where molnupiravir is not authorized for use:

• Age restrictions: It is not for use in patients younger than 18 years of age because it may affect bone and cartilage growth.
• Hospitalization: It is not used to start treatment in patients who are already hospitalized due to COVID-19, as benefit has not been shown when treatment begins after hospitalization.
• Prevention: It is not authorized for the prevention of COVID-19 (pre-exposure or post-exposure prophylaxis).

For the treatment to be effective, it must be started as soon as possible after a COVID-19 diagnosis and within five days of the first symptoms appearing.

Mechanism of Action

Molnupiravir is an antiviral drug that works by interfering with the ability of the SARS-CoV-2 virus to replicate. When a person has COVID-19, the virus enters their cells and uses the body's machinery to make copies of its genetic material, known as RNA.

Molnupiravir works by mimicking the building blocks of the virus's RNA. As the virus attempts to copy itself, it incorporates the drug into its new genetic strands. This process causes the following effects:

• Genetic Errors: The drug introduces mistakes or mutations into the virus's genetic code.
• Replication Failure: These errors prevent the virus from creating functional copies of itself.
• Reduced Viral Load: Because the virus cannot multiply effectively, the total amount of virus in the body stays lower.

By slowing down the spread of the virus within the body, molnupiravir helps the immune system manage the infection and may prevent the disease from progressing to a more severe stage.

Common Side Effects

The most frequently reported side effects of molnupiravir include:

• Diarrhea
• Nausea
• Dizziness

Serious Side Effects

While uncommon, serious allergic reactions can occur. Seek emergency medical care if you experience any of the following symptoms after taking this medication:

• Hives or skin rash
• Swelling of the face, lips, tongue, or throat
• Trouble breathing or swallowing

Molnupiravir is not authorized for use in patients younger than 18 years of age because it may affect bone and cartilage growth. If you notice any unusual symptoms or if your condition worsens while taking this medication, contact your healthcare provider immediately.

Pregnancy and Fetal Harm

Molnupiravir is not recommended for use during pregnancy. Based on findings from animal reproduction studies, this medication may cause fetal harm when administered to pregnant individuals. Healthcare providers should discuss these risks with patients who are pregnant or may become pregnant before starting treatment.

Contraception Requirements

Because of the potential for fetal harm, specific contraception guidelines are recommended:

• Females: Individuals of childbearing potential should use a reliable method of birth control consistently during treatment and for at least 4 days after the final dose.
• Males: Sexually active males with partners of childbearing potential should use a reliable method of birth control during treatment and for at least 3 months after the final dose.

Pediatric Use

This medication is not authorized for use in patients younger than 18 years of age. Studies have indicated that molnupiravir may affect bone and cartilage growth, which could interfere with the development of children and adolescents.

Breastfeeding

It is not known if molnupiravir passes into human breast milk. Because of the potential for adverse reactions in the infant, breastfeeding is not recommended during treatment and for 4 days after the final dose.

Hypersensitivity Reactions

Serious allergic reactions, including anaphylaxis and angioedema, have been reported with the use of molnupiravir. If signs of a serious allergic reaction occur—such as hives, swelling of the face, lips, or throat, or difficulty breathing—treatment should be discontinued immediately and emergency medical care should be sought.

Pregnancy

Molnupiravir is not recommended for use during pregnancy. Animal studies have indicated that the medication may cause harm to a developing fetus. Healthcare providers may only prescribe this medication to a pregnant person if they determine the potential benefits outweigh the risks in that specific situation.

If you are pregnant or could become pregnant, it is important to discuss the risks and benefits of treatment with your healthcare provider. If you discover you are pregnant while taking this medication, contact your doctor immediately.

Contraception

• Females: Individuals who can become pregnant should use effective birth control during treatment and for 4 days after the last dose.
• Males: Individuals who are sexually active with partners who can become pregnant should use effective birth control during treatment and for at least 3 months after the last dose.

Breastfeeding

It is currently unknown whether molnupiravir passes into breast milk. Due to the potential for side effects in a nursing infant, breastfeeding is not recommended while taking this medication and for 4 days after the final dose. Consult with a healthcare professional regarding the best way to feed your infant during this period.

Available Forms

Molnupiravir is currently available in one form for oral use:

• Oral Capsule: This medication is taken by mouth and can be administered with or without food.

The capsules should be swallowed whole with a sufficient amount of fluid. They should not be opened, crushed, or chewed.

Emergency Use Authorization

The U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for molnupiravir to treat mild-to-moderate COVID-19 in adults. This authorization is specifically for those who have a positive SARS-CoV-2 test and are at high risk for severe illness, including hospitalization or death.

Molnupiravir is not FDA-approved. It is authorized only for situations where other FDA-authorized COVID-19 treatments are unavailable or not clinically appropriate.

Authorized Use and Restrictions

• Age Limits: Use is restricted to adults 18 years of age and older. It is not authorized for pediatric use due to potential risks to bone and cartilage growth.
• Treatment Setting: It is not authorized for patients hospitalized due to COVID-19, as treatment should begin as soon as possible after diagnosis and within five days of symptom onset.
• Prophylaxis: The drug is not authorized for pre-exposure or post-exposure prevention of COVID-19.

Safety and Regulatory Requirements

The FDA requires healthcare providers to communicate specific information to patients or caregivers, including the Fact Sheet for Patients and Parents/Caregivers. Because of the potential for fetal harm, the drug is not recommended for use during pregnancy. Healthcare providers must verify pregnancy status for individuals of childbearing potential when appropriate before starting treatment.

How Molnupiravir Treats COVID-19

Molnupiravir is an antiviral drug designed to treat mild-to-moderate COVID-19. It is specifically intended for adults who have tested positive for the virus and are at high risk for developing severe disease, which could lead to hospitalization or death.

Mechanism of Action

The medication works by introducing errors into the genetic material of the SARS-CoV-2 virus. This process prevents the virus from multiplying correctly, thereby reducing the viral load in the body and helping the immune system manage the infection.

Usage and Eligibility

• Timing: Treatment should begin as soon as possible after a positive COVID-19 test and within five days of the first symptoms appearing.
• Patient Criteria: It is authorized for use in adults aged 18 and older for whom other FDA-authorized treatments are not accessible or clinically appropriate.
• Administration: The medication is taken orally as capsules, usually twice a day for five days.

Important Limitations

Molnupiravir is not authorized for use in children or adolescents under 18 years of age because it may affect bone and cartilage growth. It is also not used for people already hospitalized with COVID-19, as studies have not shown a benefit when the treatment is started after hospitalization. Additionally, it is not intended for the prevention of COVID-19 before or after exposure.